Acute ischemic stroke: Imaging-guided tenecteplase treatment in an extended time window

Neurology

Volumn 72, Issue 10, 2009, Pages 915-921

  Parsons, M W ^a   Miteff, F ^a   Bateman, G A ^a   Spratt, N ^a   Loiselle, A ^a   Attia, J ^a   Levi, C R ^a  

^a JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; TENECTEPLASE; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMATOMA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; IMAGE ANALYSIS; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; PERFUSION WEIGHTED IMAGING; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TIME; BRAIN ANGIOGRAPHY; BRAIN CIRCULATION; BRAIN ISCHEMIA; DOSE RESPONSE; FEMALE; IMAGE PROCESSING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; REGRESSION ANALYSIS; STROKE; TREATMENT OUTCOME;

AGED; BRAIN ISCHEMIA; CEREBRAL ANGIOGRAPHY; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; PLASMINOGEN ACTIVATORS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 64049096017     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000344168.05315.9d     Document Type: Article

References (31)

1. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.
2. Parsons MW, Barber PA, Chalk J, et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002;51:28-37.
3. Davis SM, Donnan GA, Butcher KS, Parsons M. Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Curr Opin Neurol 2005;18:47-52.
4. Neumann-Haefelin T, du Mesnil de Rochemont R, Fiebach JB, et al. Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study. Stroke 2004;35:109-114.
5. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34:537-543.
6. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38: 967-973.
7. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002;41:1229-1245.
8. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-722.
9. Al-Shwafi KA, de Meester A, Pirenne B, Col JJ. Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction. Am Heart J 2003;145:217-225.
10. Binbrek AS, Rao NS, Neimane D, Hatou E, Abdulali S, Sobel BE. Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction. Am J Cardiol 2004;93:1465-1468.
11. Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995;92:3032-3040.
12. Thomas GR, Thibodeaux H, Errett CJ, et al. A long-halflife and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 1994;25:2072-2078.
13. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005;36:607-612.
14. Brown DL, Johnston KC, Wagner DP, Haley EC. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 2004;35:147-150.
15. Molina CA, Ribo M, Rubiera M, et al. TNK induces faster MCA recanalization and leads to better short and long term clinical outcome than native tPA. Stroke 2008;39: 527. Abstract.
16. Wintermark M, Meuli R, Browaeys P, et al. Comparison of CT perfusion and angiography and MRI in selecting stroke patients for acute treatment. Neurology 2007;68: 694-697.
17. Kohrmann M, Juttler E, Fiebach JB, et al. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol 2006;5:661-667.
18. Parsons MW, Pepper EM, Chan V, et al. Perfusion computed tomography: prediction of final infarct extent and stroke outcome. Ann Neurol 2005;58:672-679.
19. Parsons MW, Pepper EM, Bateman GA, Wang Y, Levi CR. Identification of penumbra and infarct core on hyperacute non-contrast and perfusion CT. Neurology 2007;68: 730-736.
20. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581-1587.
21. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
22. Hacke K-A, Furlan A, investigators ftD. Results from the phase III study of desmoteplase in acute ischemic stroke trial (DIAS2). Cerebrovasc Dis 2007;23 (suppl 2):54.
23. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-517.
24. Wintermark M, Flanders AE, Velthuis B, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006; 37:979-985.
25. Hacke W, Kaste M, Fieschi C. Randomised double-blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-1251.
26. Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006;37:556-561.
27. Butcher K, Parsons M, Baird T, et al. Perfusion thresholds in acute stroke thrombolysis. Stroke 2003;34:2159-2164.
28. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994;91:3670-3674.
29. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7:299-309.
30. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000;55:1649-1655.
31. Barber PA, Parsons MW, Desmond PM, et al. Use of PWI and DWI measures in the design of "proof of concept" stroke trials. J Neuroimaging 2004;14:123-132.